Synergistic effects of oxymatrine and GIMAP8 in inhibiting lung adenocarcinoma progression via regulating Wnt/β-catenin pathway.

Oxymatrine is a quinolizidine alkaloid derived from Sophora roots that has demonstrated significant antitumor activity against various cancers, including lung cancer. Recently, combination therapies involving anticancer agents and targeted interventions for dysregulated genes have emerged as a promising strategy to enhance treatment efficacy and overcome drug resistance. This study investigates the synergistic effects of oxymatrine and GIMAP8 in modulating the progression of lung adenocarcinoma (LUAD). Through bioinformatics analysis and qRT-PCR, GIMAP8 was identified as a key downregulated gene in LUAD, with reduced expression confirmed in LUAD samples and cell lines. Functional cell experiments showed that GIMAP8 overexpression effectively suppressed the malignant characteristics of LUAD cells by regulating the Wnt/β-catenin pathway and inducing cell cycle arrest. Similarly, oxymatrine treatment significantly inhibited these malignant properties, and an even stronger synergistic effect was observed when oxymatrine treatment was combined with GIMAP8 overexpression, both in vitro and in vivo. In conclusion, these findings demonstrate that the combination of oxymatrine and GIMAP8 exerts synergistic antitumor effects in LUAD cells by modulating the Wnt/β-catenin pathway, supporting its potential as an effective therapeutic strategy for LUAD. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10616-025-00839-y.